ATE275416T1 - Verfahren zur verminderung von krebssymptomen - Google Patents

Verfahren zur verminderung von krebssymptomen

Info

Publication number
ATE275416T1
ATE275416T1 AT99958892T AT99958892T ATE275416T1 AT E275416 T1 ATE275416 T1 AT E275416T1 AT 99958892 T AT99958892 T AT 99958892T AT 99958892 T AT99958892 T AT 99958892T AT E275416 T1 ATE275416 T1 AT E275416T1
Authority
AT
Austria
Prior art keywords
bmp
cancer symptoms
gdf
reducing cancer
morphogen
Prior art date
Application number
AT99958892T
Other languages
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
David C Rueger
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22704676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275416(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ATE275416T1 publication Critical patent/ATE275416T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AT99958892T 1998-11-13 1999-11-12 Verfahren zur verminderung von krebssymptomen ATE275416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19123998A 1998-11-13 1998-11-13
PCT/US1999/026636 WO2000029012A2 (en) 1998-11-13 1999-11-12 Methods of alleviating cancer symptoms

Publications (1)

Publication Number Publication Date
ATE275416T1 true ATE275416T1 (de) 2004-09-15

Family

ID=22704676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958892T ATE275416T1 (de) 1998-11-13 1999-11-12 Verfahren zur verminderung von krebssymptomen

Country Status (10)

Country Link
EP (2) EP1435243A3 (de)
JP (2) JP4892131B2 (de)
AT (1) ATE275416T1 (de)
AU (1) AU1616700A (de)
CA (1) CA2349038C (de)
DE (1) DE69920033T3 (de)
DK (1) DK1131087T4 (de)
ES (1) ES2226467T5 (de)
PT (1) PT1131087E (de)
WO (1) WO2000029012A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
KR101008758B1 (ko) * 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
WO2006029406A2 (en) * 2004-09-09 2006-03-16 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins
JP2008169116A (ja) * 2005-04-18 2008-07-24 Tokyo Medical & Dental Univ Ｂｍｐ−７を含む抗ｃ型肝炎ウイルス剤
ATE520711T1 (de) 2005-05-27 2011-09-15 Bbs Bioactive Bone Substitutes Oy Knochenmorphogenetisches protein 4 und osteogene vorrichtungen und pharmazeutische produkte, die dieses enthalten
WO2006125866A1 (en) 2005-05-27 2006-11-30 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof
US7910552B2 (en) 2005-05-27 2011-03-22 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
PL3117833T3 (pl) * 2005-07-19 2019-06-28 Stemgen S.P.A. Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza
GB0615129D0 (en) * 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399569B1 (en) * 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
ES2161693T3 (es) † 1991-03-11 2001-12-16 Curis Inc Morfogenesis inducida por proteinas.
US5652118A (en) † 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DK0653942T3 (da) † 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
EP0680334B1 (de) * 1992-09-15 2000-12-13 Creative Biomolecules, Inc. Behandlung von magen- und darmgeschwüren mit morphogenen
DE69535641D1 (de) † 1994-04-29 2007-12-27 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
JPH08225454A (ja) * 1995-02-23 1996-09-03 Chugai Pharmaceut Co Ltd マイクロスフェア製剤
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
AU7115996A (en) † 1995-09-21 1997-04-09 Trustees Of Columbia University In The City Of New York, The Uses of bone morphogenetic proteins
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease

Also Published As

Publication number Publication date
DK1131087T4 (da) 2009-08-03
DK1131087T3 (da) 2004-12-13
JP2002529513A (ja) 2002-09-10
WO2000029012A3 (en) 2000-11-16
WO2000029012A8 (en) 2001-01-11
DE69920033T3 (de) 2009-10-08
EP1131087B1 (de) 2004-09-08
EP1435243A2 (de) 2004-07-07
CA2349038A1 (en) 2000-05-25
CA2349038C (en) 2011-08-02
PT1131087E (pt) 2004-12-31
DE69920033T2 (de) 2005-09-22
EP1131087B2 (de) 2009-04-01
EP1435243A3 (de) 2005-02-09
DE69920033D1 (de) 2004-10-14
ES2226467T5 (es) 2009-08-27
EP1131087A2 (de) 2001-09-12
AU1616700A (en) 2000-06-05
JP4892131B2 (ja) 2012-03-07
WO2000029012A2 (en) 2000-05-25
JP2010150278A (ja) 2010-07-08
ES2226467T3 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
CY1110570T1 (el) Χρηση της ουριδινης σε συνδυασμο με χολινη για τη θεραπεια διαταραχων της μνημης
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
PT1333887E (pt) Metodo de tratamento de desordens musculares
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
SE9900100D0 (sv) New compounds
EP2082749A3 (de) Vorbeugung und Behandlung für Morbus Alzheimer
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
DE69920033D1 (de) Verfahren zur verminderung von krebssymptomen
EP0949920A4 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
WO2000013650A3 (en) Neuroprotection
KR960006915A (ko) 췌장염의 치료 조성물
EP1181935A3 (de) Mittel zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DE19580965D2 (de) Rasterbild und Thermotransferfolie zu dessen Herstellung
Font et al. Finding the words: Instruments for a therapy of liberation
ZA951293B (en) 4-amino derivatives of 5-substituted mycophenolic acid
MY124089A (en) Use of cetirizine for preventing the onset of asthma
BR0017035A (pt) Combinação de trimebutina com um analgésico opióide
CA2452432A1 (en) Active ingredient combination for the pharmacological therapy of nicotine dependence
IT1319487B1 (it) Procedimento atto alla regolazione di un'operazione di avviamento inautoveicoli
CA2248753A1 (en) Use of olanzapine for treating excessive aggression
BR9714382A (pt) 17alfa-diidroequilina para uso como um antioxidante médico
ES2162062T3 (es) Estabilizacion de nitrilos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131087

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1131087

Country of ref document: EP

EEIH Change in the person of patent owner